Described is a method for treating an individual having a neurological disorder withan associated mutation or mutations in a gene encoding a lysosomal enzyme. Specifically,the individual is administered a specific pharmacological chaperone for thelysosomal enzyme which increases trafficking of the protein from the ER to thelysosome in neural cells, with or without concomitantly increasing enzyme activityin neural cells. Restoration of trafficking relieves cell stress and other toxicitiesassociated with accumulation of mutant proteins. Restoration of enzyme activityrelieves substrate accumulation and pathologies associated with lipid accumulation.In a specific embodiment, the neurological disorder is Parkinson's diseaseor parkinsonism which is associated with mutations in glucocerebrosidase.
